|
Patent Happenings April 2009
|
1. Federal Circuit to consider en banc whether ¤ 271(f) applies to process claims
4. Claims to a ÒparadigmÓ for marketing software failed to claim patent eligible subject matter
6. Precritical date testing of durability to satisfy government regulators was not an experimental use
7. Employee who only contributed a feature that was already in the prior art was not a joint inventor
9. Dismissal of infringement claim as a discovery sanction reversed
Sections ¤ 271(f)(1) and (f)(2) of the Patent Act make an infringer liable, under certain circumstances, for exporting from the United States components that when combined abroad result in a combination that would infringe a U.S. patent if the combination was made in the United States.[1] Whether ¤ 271(f) applies to process claims had been a point of contention in patent law.[2] In its 1991 opinion in Standard Havens Prods, the Federal Circuit appeared to hold that ¤ 271(f) did not apply to method claims.[3] But in its 2005 opinions of Eolas Technologies[4] and Union Carbide,[5] the Federal Circuit held that ¤ 271(f) does reach process patents.[6]
In 2007, the Supreme Court handed down its opinion in Microsoft Corp. v. AT & T Corp., 550 U.S. 437 (2007), which addressed aspects of ¤ 271(f). Although the Supreme Court did not address the applicability of ¤ 271(f) to process claims, some of the CourtÕs holdings may raise questions as to the continued vitality of the Federal CircuitÕs rationale for ruling that ¤ 271(f) applies to process claims. For example, one of the reasons the Federal Circuit relied on for construing ¤ 271(f) to apply to process claims was its conclusion that the term ÒcomponentÓ in ¤ 271(f) extends beyond physical objects, and therefore could reach a process.[7] But, in Microsoft, the Supreme Court expressly considered whether ¤ 271(f) reaches intangible or abstract objects and ruled that it did not. The Court held that Òan idea without physical embodiment . . . does not match ¤ 271(f)Õs categorization: ÔcomponentsÕ amenable to Ôcombination.ÕÓ[8]
The issue of whether ¤ 271(f) applies to process claims in view of Microsoft has gotten the attention of the Federal Circuit. On March 6, 2009, the Federal Circuit, in the matter of Cardiac Pacemakers, Inc. v. St. Jude Medical, Inc.,[9] granted an accused infringerÕs petition for an en banc rehearing to determine whether ¤ 271(f) applies to process claims.
In Cardiac Pacemakers, the patentee sought damages under ¤ 271(f) for foreign sales of accused products that were used abroad to practice the claimed method. In March 2006, and before the Supreme Court handed down its opinion in Microsoft Corp., the district court denied the accused infringerÕs motion for summary judgment seeking to exclude such sales from the damages pool based on the contention that ¤ 271(f) does not apply to process claims. But the district court remarked that the accused infringerÕs arguments that ¤ 271(f) should not apply to method claims had Òconsiderable weightÓ because merely assembling the completed apparatus did not infringe the method claim; only the use of the assembled product, an additional act, infringed the method claim if done in the United States.[10] Nevertheless, in view of Union Carbide, the district court held that it could not Òconclude as a matter of law that section 271(f) does not apply to the method claim at issue here.Ó In a nonprecedential opinion, a panel of the Federal Circuit affirmed.[11] The panel rejected the accused infringerÕs argument that Microsoft overturned Union Carbide. Id.[12]
In its order granting the petition for en banc rehearing, the Federal Circuit has ordered the patentee to submit a brief addressing a single question: ÒDoes 35 U.S.C. ¤ 271(f) apply to method claims, as well as product claims?Ó The patenteeÕs brief appears to be due on Monday April 6, 2009, with the accused infringerÕs response due twenty days after service of the patenteeÕs brief, and the patenteeÕs reply due seven days later. The court also order that amicus briefs could be filed without leave of court. Oral argument is set for Friday, June 1, 2009.
The marking statute, 35 U.S.C. ¤ 287(a), generally requires patentees to mark their products covered by the patent with the patent number as a prerequisite to recovering damages for any infringement done before the patentee filed suit or before it gave the accused infringer actual notice of the patent and its charge of infringement.[13] By its express terms the marking statute only applies to Òpatented articles.Ó[14] Accordingly, the Federal Circuit has held that no requirement to mark applies to process patents.[15] But, the court has also instructed, in American Medical Sys., that Òto the extent that there is a tangible item to mark by which notice of the asserted method claims can be given, a party is obliged to do so.Ó[16]
When faced with its failure to mark its product with the patent number of its patent having both apparatus and method claims, some patentees have argued that the marking requirement should not apply where the patentee only asserts the method claims.[17] Relying on American Medical, district courts in the past have almost routinely rejected this argument.[18]
Shaking up the law in this area, the Federal Circuit in Crown Packaging Technology, Inc. v. Rexam Beverage Can Co., No. 2008-1284, -1340, 2009 WL 678743, *5-*6 (Fed. Cir. Mar. 17, 2009), reversed a summary judgment that a patentee could not avoid its failure to mark by asserting only method claims where its patent had both apparatus and method claims.
The patentee in Crown had permitted its licensee to make and sell ÒneckingÓ machines. The licensee did not mark the machines. The patentee had a patent that covered the necking machine via apparatus claims and also covered processes that could be carried out with the necking machine. Other noninfringing processes could also be performed with the necking machine. While the patentee did not require its licensee to mark, it did require its licensees to inform purchasers that they needed to obtain a license from the patentee if they wished to use the necking machine in the configurations under which it practiced the claimed methods. Id. at *5
When the patentee asserted its patent against the plaintiff as an infringement counterclaim, the district court granted the plaintiff summary judgment that the patenteeÕs failure to require its licensee to mark the necking machines defeated all claims for pre-suit damages. Further, since the patent had expired, the inability to recover any pre-suit damages warranted dismissing the infringement counterclaim. In granting summary judgment, the district court rejected the patenteeÕs argument that since the patentee only asserted the process claims, it had no duty to mark.[19] Taking a practical view of implementing the policy of giving constructive notice of patent rights, the district court stated: ÒRexamÕs argument, that it was not required to mark because it was only asserting method claims, is at odds with the very purpose of the marking statute: Ôto avoid innocent infringement, encourage patentees to give public notice of patent protection, and aide the public in identifying patented articles.Õ Regardless of whether or not it asserted method claims, apparatus claims or both, Rexam was required to mark and have its licensee, Belvac, mark products in order to obtain the benefits of the constructive notice provisions set forth in section 287(a).Ó Nonetheless, on appeal the Federal Circuit held that the district court erred.
Writing for the court, Judge Moore explained that the panel was bound to follow the prior precedent of Hanson.[20] According to Judge Moore, Hanson stands for the proposition that Ò35 U.S.C. ¤ 287(a) did not apply where the patentee only asserted the method claims of a patent which included both method and apparatus claims.Ó Id. at *6. Ruling that the facts in Crown were ÒidenticalÓ to the facts in Hanson, the ÒfactsÓ apparently just being that the patentee in Crown only asserted method claims, the court concluded no duty to mark arose. Id.
Judge Moore distinguished Hanson over American Medical on the basis that in American Medical the patentee had asserted both apparatus and method claims. Id. Interestingly, the court did not address Devices for Medicine,[21] a case in which it held that the patenteeÕs failure to mark its product that had no use but to practice the claimed method precluded recovering damages for infringement of the process claims. Since the patentee in Devices for Medicine had asserted both its apparatus and method claims, the Crown panel would have likely applied the same distinction.
While the distinction drawn by the Crown court regarding Hanson and American Medical (and equally applicable to Devices for Medicine) is technically accurate, it seems superficial and unsatisfying. As noted in the APD, one possible substantive
distinction that appears to have more merit lies in the differences between the claimed process in American Medical and Devices for Medicine and that in Hanson. In American Medical, the court noted that the patenteeÕs product was a Òphysical device produced by the claimed method.Ó In Devices for Medicine, the claimed process was the intended use of the claimed apparatus. In both of these cases, infringement of the process claim depended on the presence of the apparatus. In Hanson, the claimed process concerned a method of making snow. While the sold apparatus, which was allegedly covered by the apparatus claim, could be used to practice the process of making snow, the apparatus was not the outcome of the process, nor was the presence of the apparatus crucial for practicing the claimed process. The snow could be made by means wholly independent of the apparatus, and the process claims did not recite the use of the apparatus as an element of any of the claims. Thus, the claimed process in Hanson was independent of the claimed apparatus. This suggests that where a process can only be infringed by the use or creation of an article sold by the patentee or its licensee, then that article should be marked with the process patent number. If the process can be performed without the patenteeÕs article, the law might not require marking. Although this seems contrary to the policy stated in American Medical ÐÐ Òto the extent that there is a tangible item to mark by which notice of the asserted method claims can be given, a party is obliged to do so.Ó[22]
While the facts recited by the court in Crown note that the unmarked patented necking machine could be used in ways that did not practice the claimed processes, the facts were silent as to whether the claimed processes could be practiced in ways that did not require the use of the patented necking machine. If not, and if Òthe claimed method is the use of the product,Ó then perhaps the failure to mark the necking machines should have precluded damages under Devices for Medicine.[23]
Pursuant to PTO Rule 56, attorneys must disclose to the PTO all noncumulative material information of which they have knowledge.[24] This duty can, under certain circumstances, extend to requiring the disclosure of copending applications and specific papers contained therein.[25] As shown by Dayco Products,[26] the duty to disclose copending patent applications may be heightened when the examiner in one application rejects a claim that is substantially similar to a claim in the copending patent application. Even though an examiner is not duty bound to repeat a rejection of another examiner, such a rejection may readily meet the standard for materiality. The Federal Circuit reaffirmed this principle in Larson Mfg. Co. of SD, Inc. v. Aluminart Products Ltd., No. 2008-1096, 2009 WL 691322, *14-*15 (Fed. Cir. Mar. 18, 2009).
In Larson, the court found that prior art rejections made in a third and fourth office actions of a continuation application were material to the prosecution of a copending reexamination proceeding since the claims under consideration in the reexamination were substantially similar to the rejected claims of the continuation application. Id. Explaining why it found the office actions material, the court remarked that Òknowledge of a potentially different interpretation is clearly information that an examiner could consider important when examining an application.Ó Id. at *14.
The patentee argued that the third office action lost its materiality when the Examiner later withdrew the rejection, after concluding that the applicant had correctly explained that the prior art reference did not disclose a feature the examiner thought it did. Rejecting this argument, the Federal Circuit instructed that the later development did not nullify the materiality of the earlier rejection to the reexamination proceeding because the office action Òcontained valuable reasoning and rejections at the time when it was made,Ó which remained of record for approximately a year. Id. at *15. As to the fourth office action, the court found that because it contained an adverse decision of the examiner in the continuation application, based on a different explanation and interpretation of the same prior art references the reexamination examiner was considering, the fourth office action Òwas Ôclearly information that an examiner could consider important.ÕÓ Id.
Remanding the case back to the district court, in view of errors the district court made as to other withheld prior art references, the Federal Circuit provided ÒguidanceÓ to the district court on analyzing the issue of intent to deceive. Id. at *16. Apparently seeking to temper a too liberal application of an inference of intent to deceive, the Federal Circuit repeated its recent pronouncement in Star Scientific,[27] that to meet the clear and convincing evidentiary burden, the inference that the applicant intended to deceive the PTO must be the Òsingle most reasonable inferenceÓ that can be drawn from the circumstantial evidence. Id. at *16. Addressing inferences of intent drawn where the patentee fails to offer a credible good faith explanation for why it withheld material information,[28] the court further instructed that Òjust as merely withholding a reference cannot support an inference of deceptive intent, so too an accused infringer cannot carry its threshold burden simply by pointing to the absence of a credible good faith explanation.Ó Id.
The court also instructed that in evaluating the issue of intent to deceive, the district court had to take into account that the patentee had disclosed to the PTO in the reexamination proceeding the pleadings filed in the current case, which included the accused infringerÕs other inequitable conduct allegations and invalidity challenges, and that the patentee had fully informed the reexamination examiner about the continuation application and had even provided the first two office actions in the continuation application to the reexamination examiner. The Federal Circuit noted that this evidence Òpoints away from deceptive intent and must be given weight.Ó Id.
Despite these cautionary instructions, Judge Linn in a concurring opinion expressed his concern that the courtÕs jurisprudence regarding inequitable conduct has become Òproblematic.Ó Id. at *19. He stated his view, that Ò[t]he ease with which inequitable conduct can be pled, but not dismissed, is a problem of our own making.Ó Id. at *18. Although not explicitly calling for raising the standard of what conduct constitutes inequitable conduct, Judge Linn did note that all three of the Supreme Court cases addressing inequitable conduct involved Òovert fraud.Ó Id. Examining the courtÕs legal standards for inferring an intent to deceive, he concluded the test Òfalls short of the standard Ôneeded to strictly enforce the burden of proof and elevated standard of proof in the inequitable conduct context.Ó Id. at *20. Accordingly, he suggested that Òthe time has come for the court to review the issue en banc.Ó Id. Given Judge RaderÕs relatively recent statements in Aventis Pharma S.A.,[29] expressing similar views that inherent problems exist with the standards for inferring intent to deceive, momentum may be growing within the Federal Circuit for an en banc consideration of this issue, if the Supreme Court does not grant the petition for certiorari in Aventis.
In its second published post-Bilski opinion[30] addressing the patentability of business-method related claims, the Federal Circuit in In re Ferguson, No. 2007-1232, 2009 WL 565074 (Fed. Cir. Mar. 6, 2009), affirmed rejections of claims directed to methods of marketing and a Òparadigm for marketing softwareÓ for claiming patent ineligible subject matter under ¤ 101.
The inventors sought claims directed to Òa method of marketing a productÓ requiring the steps of Òdeveloping a shared marketing force,Ó Òusing said shared marketing force to market a plurality of different products that are made by a plurality of different autonomous producing compan[ies],Ó Òobtaining a share of total profits from each of said É companies,Ó and Òobtaining an exclusive right to market each of said . . . products[.]Ó Applying Bilski,[31] the Federal Circuit, in a majority opinion written by Judge Gajarsa and joined by Judge Mayer, held that the method claims fail the machine-or-transformation test because the claims are not Òtied to any particular machine or apparatus.Ó Id. at *3. The majority rejected the applicantsÕ argument that because the method claims recite the use of a Òshared marketing force,Ó the claims pass muster under Bilski. Applying the definition of a ÒmachineÓ used in Nuijten,[32] Ð Òa machine is a concrete thing, consisting of parts, or of certain devices and combination of devices . . . [that uses a] combination of mechanical powers and devices to perform some function and produce a certain effect or resultÓ Ð the court held that a marketing force does not qualify as a Òmachine.Ó Id. According to the court, organizing and structuring a sales force transforms private legal obligations and relationships. It fails the test for patentability because the relationships of the sales force Òare not physical objects or substances, and they are not representative of physical objects or substances.Ó Id. at *4. Hence, the court viewed the attempt to claim the relationships in the sales force as being an unpatentable abstract idea. Id.
Illustrating how BilskiÕs machine-or-transformation test is indeed now the sole test for determining patent eligibility for process inventions, the court additionally rejected the applicantsÕ request to consider a Ònew testÓ of whether the Òclaimed subject matter require[s] that the product or process has more than a scintilla of interaction with the real world in a specific way?Ó Id. at *4.
In a creative attempt to protect the business method in a non-process claim form, the applicants also presented claims directed to a Òparadigm for a marketing software, comprising a marketing company that markets software from a plurality of different independent and autonomous software companies É.Ó Id. at *1. Applying the methodology used in Nuijten to find that claims directed to electrical signals did not claim patent eligible subject matter, the Federal Circuit considered whether the ÒparadigmÓ fell within the scope of any of the four categories of patentable subject matter: process, machine, article of manufacture, or composition of matter. The court easily concluded that the ÒparadigmÓ claims did not fall within the categories of process, article of manufacture, or composition of matter, and the applicants had not argued otherwise. Id. at *5. Instead, the applicants argued that the marketing company of the ÒparadigmÓ is analogous to a Òmachine.Ó Essentially applying the same rationale used to reject the applicantsÕ argument that its method claims are tied to a Òmachine,Ó the court rejected the contention that the ÒparadigmÓ is directed to a machine. The Federal Circuit explained Òthe paradigm claims do not recite Ôa concrete thing, consisting of parts, or of certain devices and combination of devices,Õ and as Applicants conceded during oral argument, Ôyou cannot touch the company.Õ To the contrary, Applicants do no more than provide an abstract ideaÑa business model for an intangible marketing company. ApplicantsÕ argument is, therefore, unavailing. Absent identity with any statutory category, ApplicantsÕ paradigm claims are, therefore, unpatentable as not directed to statutory subject matter.Ó Id.
Judge Newman concurred in the judgment since she believed the PTO correctly rejected the claims for being obvious in view of the prior art. Id. at *7. She disagreed with the majorityÕs characterization of the claimed invention as an Òabstract ideaÓ and chided the majority for effectively adopting a test that anything that does not meet BilskiÕs test for patent eligibility is an abstract idea. Id. at *6-*7.
Making a call for judicial restraint, Judge Newman further stated:
Until we are confident in understanding the consequences of our rulings, let us not forget that todayÕs Òknowledge economyÓ arose and thrived under the past law of patent eligibility. Although I agree that new thinking is warranted, this courtÕs broadside assault on patent-eligible subject matter is unsupported by any stated policy or benefit to either society or commerce. We are ignorant of whether competitive activity, creative energies, and entrepreneurial initiatives, will founder or be facilitated by this courtÕs dramatic change in the legal framework. . . . [M]uch more needs to be understood, as this court undertakes to change the legal framework of this economy. . . . This courtÕs retreat into the methods of the past is unworthy of our responsibility to support innovation in the future. Major adjustment in established law should be based on changing industrial or intellectual or equitable needs Ð of which no evidence is before this court. The only need of which I am aware is that of the current harsh economic times, when the need is of enhanced incentives to innovation and investment in new things and new industries, not reduction in the existing incentives.
Id. at *7.
Showing what perhaps may be a rift growing in the court, the majority dismissed Judge NewmanÕs comments as being Òpremised on policy and philosophical grounds.Ó Id. at *5 n.7. Judge Gajarsa stated that he Òdisagree[d] with this approach, as it is not the role of courts to make such arguments but rather the responsibility of Congress to consider amending the patent laws as necessary to recognize and allow for innovation in the future.Ó Id. Responding to the majorityÕs criticism by relying on the observations of Justice Holmes in his famous work The Common Law where he explained that public policy concerns shape and underlie virtually all legal doctrines, Judge Newman explained that her Òmajor concern with [her] colleaguesÕ aggressive elimination of patent access in areas of modern commerce is their failure to consider the policy effects.Ó Id. at *7 n.1.
Long ago, the Supreme Court instructed that an Òapplication for a patent cannot be broadened by amendment so as to embrace an invention not described in the application as filed, at least when adverse rights of the public have intervened.Ó[33] The Federal Circuit applied this principle in the famous case of Gentry Gallery,[34] where it held that claims added by amendment and directed to a sectional sofa having reclining controls, but that did not limit the location of the controls to be on a console, failed the written description requirement because the specification only described the controls as being on the console.[35] While some viewed Gentry Gallery as establishing a requirement that claims must claim all Òessential elementsÓ of the invention, the Federal Circuit rejected the concept of an Òessential elementÓ test in Cooper Cameron.[36] Nonetheless, the Federal Circuit has maintained that Gentry Gallery illustrates Òthe settled principle that a broadly drafted claim must be fully supported by the written description and drawings.Ó[37] The Federal CircuitÕs recent opinion in ICU Medical, Inc. v. Alaris Medical Systems, Inc., No. 2008-1077, 2009 WL 635630, *6-*7 (Fed. Cir. Mar. 13, 2009), illustrates, yet again, that in some instances amending a claim to omit a previously claimed element can render the claim invalid for failing the written-description requirement.
The claims at issue in ICU Medical concerned a medical valve used to connect a syringe to an infusion line without the use of a needle. In the specification the inventors described all embodiments of the invention as having a spike that was used to pierce a seal in making the connection. The Federal Circuit found that nothing in the specification suggested that the invention could be made without using the spike. All of the claims originally submitted by the inventor recited a spike. Several years into the prosecution, and after a competitor introduced a competing valve product that did not use a spike, the inventors added new claims that omitted the spike from the claims. The district court granted the accused infringer summary judgment that the ÒspikelessÓ claims were invalid for failing to have an adequate written description. The Federal Circuit affirmed.
On appeal, the Federal Circuit rejected the patenteeÕs argument that the specificationÕs disclosure of valves with spikes supported Òclaims that are neutral regarding whether the valve must include a spike.Ó The Federal Circuit noted that the challenged claims covered valves with spikes and valves without spikes. Id. at *6. Accordingly, to meet the written description requirement, the court concluded that the specification had to disclose valves with spikes and valves without spikes. The court found there was no factual dispute that the specification had no disclosure showing a valve without a spike. Id.
In an attempt to show that the specification disclosed a spikeless embodiment, the patentee argued that the specification disclosed the use of a pre-slit, and one of skill in the art would realize that the pre-slit could be used to make a spikeless valve. Noting that the pre-slit was only disclosed as a way to facilitate the spike piercing the seal, and not as a way to eliminate the need to have a spike that could pierce a seal, the Federal Circuit rejected this argument. It instructed that the Ò[i]t is not enough that it would have been obvious to a person of ordinary skill that a preslit trampoline seal could be used without a spike.Ó Id. at *7.[38]
The Federal CircuitÕs analysis in ICU Medical, where it first determined that the claim covered two distinct embodiments Ð valves with spikes and valves without spikes Ð and then looked to see if the specification adequately described each of these distinct embodiments, appears very similar to the analysis it has applied in the enablement context. In assessing whether a specification enables the full scope of a claim where the claim covers two distinct embodiments, the Federal Circuit has demanded that the specification provide an enabling disclosure for both distinct embodiments.[39] Although the Federal Circuit did not cite to its enablement cases in ICU Medical, it appears to have applied the same principle in analyzing whether the full scope of the claimed invention had been adequately described.
The doctrine of Òexperimental negationÓ provides that a public use or sale of an invention that would otherwise render the claims to the invention invalid under ¤ 102(b) will not invalidate the claims if the use or sale was done primarily to experiment with the claimed invention by testing it to improve its qualities before the invention is reduced to practice.[40] The doctrine arose from the belief that Òallowing inventors to experiment to perfect their inventions before applying for a patent serves the public by giving the public a better invention.Ó[41] Not all alleged ÒexperimentalÓ uses of an invention will negate a prior public use. As shown by the Federal CircuitÕs opinion in Clock Springs, L.P. v. Wrapmaster, Inc., No. 2008-1332, 2009 WL 766268, *4-*8 (Fed. Cir. Mar. 25, 2009), to qualify for Òexperimental negation,Ó the public use must be for the purposes of testing aspects of the claimed invention related to filing a patent application,[42] not for making the invention commercially attractive.[43]
In Clock Springs, the court affirmed a summary judgment holding claims directed to a method of repairing a damaged pipe invalid based on the inventor publicly demonstrating the method to industry regulators three years before it filed its patent application. The patentee argued that the demonstration was experimental since the inventor sought to test the durability of the repair made with the method. Accepting the contention that industry reports written years later supported an inference that the demonstration sought to test the durability of the repair, the Federal Circuit, nonetheless, concluded that as a matter of law the demonstration was not experimental. It explained that Ò[a] use may be experimental only if it is designed to (1) test claimed features of the invention or (2) to determine whether an invention will work for its intended purpose[.] . . . But, there is no experimental use unless claimed features or overall workability are being tested for purposes of the filing of a patent application.Ó Id. at *7. Considering the test reports submitted by the patentee documenting the public demonstration, the Federal Circuit noted that nothing in the test reports indicated that the inventor was seeking to test aspects of the limitations of the claims. Rather, the inventor was seeking to test the commercial durability of the repairs achieved by the method so that the method would be approved by the regulators for commercial use. The court found further confirmation that the public demonstration was not for purposes of filing the patent application by noting that the pipes repaired with the claimed method in 1989 were dug up to examine how well the repair held up a year after the patent application had been filed. Hence, the court concluded that Òeven if durability were being tested, it was not for purposes of the patent application, and cannot bring the experimental use exception into play.Ó Id.
The patentee also argued that since government regulations legally prohibited it from commercially using its claimed method until a year after it filed its patent application, its earlier demonstration must have been experimental. The Federal Circuit instructed that even if Òthe inventors were not legally allowed to perform the method on a pipeline in commercial operation, [that] does not mean that a public use did not occur. The former fact has absolutely nothing to do with the latter question.Ó Id. at *8.
With its focus on rewarding the actual inventors, U.S. patent law requires that when an invention is jointly conceived by persons working together, the patent must be applied for in the name of all the individuals who are Òjoint inventors.Ó[44] To delineate when an individual qualifies as a joint inventor, the Federal Circuit has developed a standard that joint inventorship requires that each joint inventor must Ò(1) contribute in some significant manner to the conception or reduction to practice of the invention, (2) make a contribution to the claimed invention that is not insignificant in quality, when that contribution is measured against the dimension of the full invention, and (3) do more than merely explain to the real inventors well-known concepts and/or the current state of the art.Ó[45]
In view of factor 3, Federal Circuit case law recognizes that an individual does not attain the status of being a joint inventor by only contributing the exercise of ordinary skill in the art since that contribution does not contribute to the conception of the claimed invention.[46] Illustrating this principle, the Federal Circuit in Nartron Corp. v. Schukra U.S.A., Inc., No. 2008-1363, 2009 WL 539912, *4-*6 (Fed. Cir. Mar. 5, 2009), rejected an accused infringerÕs attempt to show that the asserted patent failed to name a joint inventor. The asserted patent claimed a control module for an automobile seat having massage capabilities. The invention focused on the electronic control of various seat components, including a lumbar support adjustor. One of the dependent claims claimed the feature that the lumbar support adjustor had an Òextender.Ó The accused infringer alleged that the inventors named on the patent did not conceive of the idea of using a lumbar support adjustor with an extender, but rather that aspect of the invention was conceived by an employee of one of the accused infringers who had not joined the suit. The district court agreed with the accused infringer and dismissed the suit for failing to join the employee.[47] On appeal the Federal Circuit reversed.
The Federal Circuit noted that the use of an extender on a lumbar support adjustor of an automobile seat, the employeeÕs alleged contribution to the claimed invention, was in the prior art. Accordingly, the court found that Òthe contribution of the extender is insignificant when measured against the full dimension of the invention of claim 11, not just because it was in the prior art, but because it was part of existing automobile seats, and therefore including it as part of the claimed invention was merely the basic exercise of ordinary skill in the art.Ó Id. at *4. The court further noted that while the alleged omitted inventor may have researched specific extenders to use, the patent only disclosed and claimed the extender in general and basic terms. Since the prior art already taught using extenders in automobile seats, the employeeÕs alleged contribution to the invention did not rise to a contribution of a joint inventor. Id. at *5. The Federal Circuit stressed that Ò[t]his is not a case in which a person claims to be an inventor because he has suggested a non-obvious combination of prior art elements to the named inventors. Such an individual may be a co-inventor. There is not, and could not be, any claim that the addition of the extender here was anything but obvious. BensonÕs contribution therefore does not make him a co-inventor of the subject matter of claim 11.Ó Id.
Rule 706 of the Federal Rules of Evidence permits a district court to appoint a neutral expert witness to testify at trial.[48] The Federal Circuit confirmed in Monolithic Power Systems, Inc. v. O2 Micro International Ltd., No. 2008-1128, 2009 WL 539910, *3 (Fed. Cir. Mar. 5, 2009), that district courts have the power to appoint technical experts to testify on issues of infringement and invalidity. There, after concluding that the electrical engineering issues raised by the infringement and invalidity issues were so complicated, that that jury would likely never understand the parties competing experts, the district court required the parties to agree on a third expert that the court would appoint as a neutral expert. During the trial, the appointed expert witness testified on his opinions of invalidity and infringement. The district court explained to the jury that the expert had been appointed by the court to act as an independent expert. The district court also gave the jury a cautionary instruction that the jury was not to give the appointed expertÕs testimony Ògreater inherent weightÓ based on the expertÕs independent status. Of the two claims at issue, the appointed expert testified that the first claim was infringed but invalid for obviousness, and the second claim was not infringed and was not obvious. The jury found both claims infringed, and both claims invalid for obviousness.
The Federal Circuit rejected the patenteeÕs argument that the use of the court-appointed expert and informing the jury as to the independent status of the expert Òunduly burdenedÓ the patenteeÕs Seventh Amendment right to a jury trial. Examining the procedure employed by the district court, the Federal Circuit held that the district court had not abused its discretion in using the appointed expert. The Federal Circuit found that the district court had followed all of the requirements of Rule 706. The district court Òallowed the parties to show cause why an expert witness should not be appointed, and over [the patentee]Õs objections, instructed the parties to nominate candidates and confer upon a mutually agreeable witness.Ó Id. at *4. The district court gave the expert detailed written instructions regarding his duties, and ordered the expert to make himself available for depositions and for examination at trial. Id. The parties shared the expertÕs reasonable fees and expenses. Id. The district court did not limit in any way the partiesÕ ability to call their own experts to attack, support, or supplement the testimony of court appointed expert. Id.
Finally, the Federal Circuit also found that the district court did not abuse its discretion when it disclosed to the jury the appointed expertÕs independent status, in full accordance with Rule 706. Id. at *4-*5. The Federal Circuit characterized the patenteeÕs objections to disclosing the independent status of the expert to the jury as policy arguments that had been rejected by Congress in enacting Rule 706(c).[49] Id. at *5. Nonetheless, while finding no abuse of discretion by the district court, the Federal Circuit stated that Ò[t]he predicaments in court appointment of an independent expert and revelations to the jury about the expertÕs neutral status trouble this court to some extent.Ó Id. It thus cautioned that Ò[c]ourts and commentators alike have remarked that Rule 706 should be invoked only in rare and compelling circumstances.Ó Id.
Rule 37(b)(2)(A)(v) of the Federal Rules of Civil Procedure permits a district court to dismiss an action as a sanction for violating a discovery order. As shown by the Federal CircuitÕs recent decision in ClearValue, Inc. v. Pearl River Polymers, Inc., No. 2007-1487, 2009 WL 750176 (Fed. Cir. Mar. 24, 2009), this Òdeath knellÓ sanction is generally reserved for the truly egregious cases.[50]
In ClearValue, the district court (Judge Davis of the E.D. of Texas), found that during discovery a patentee and its counsel intentionally failed to produce results of some testing done on the accused product that had been shared with the patenteeÕs testifying expert witness. The results of the testing raised questions as to whether the accused product infringed. For the discovery violation, the district court awarded a series of sanctions including an award of attorneyÕs fees under Rule 37(b) and an order dismissing the patenteeÕs infringement claims and granting the accused infringer a default judgment on its invalidity counterclaims.
On appeal, the Federal Circuit affirmed the district courtÕs finding of sanctionable conduct. The Federal Circuit found that since the test results had been disclosed to the patenteeÕs testifying expert, the patentee had a duty under Rule 26 to produce the test results to the accused infringer even though the patenteeÕs testifying expert may not have relied on the test results in reaching his opinion.[51] Id. at *9-*11. Applying the abuse of discretion standard, and noting the deferential standard of review given to a district courtÕs findings as to witness credibility, the Federal Circuit concluded that the district court had not abused its discretion in ruling that the patentee and its counsel had engaged in sanctionable conduct that harmed the accused infringer. Id. at *11. Accordingly, the Federal Circuit found that the district court appropriately awarded attorneyÕs fees under Rule 37(b) as a sanction. Id. at *12.
Applying Fifth Circuit precedent, however, the Federal Circuit reversed the sanction ordering the dismissal of the infringement claims and default judgment on the invalidity counterclaims. Id. at *14-*15. The court noted that under Fifth Circuit law, a dismissal sanction must be a Òremedy of last resort.Ó Id. at *14. Comparing the egregiousness of the patenteeÕs discovery violation to Fifth Circuit cases where the Fifth Circuit refused to impose the death knell sanction, which included cases where the sanctioned party altered evidence or destroyed evidence, the Federal Circuit held that the patenteeÕs conduct did not rise to a level that supported a dismissal sanction. Id. at *15.
Patent reform appears to be on a fast track in Congress. In early March, bills to continue last yearÕs efforts to revise the Patent Act were introduced in Senate and the House. The Senate Judiciary Committee held a day of hearings the second week of March, mostly addressing the proposed damages provisions. Thereafter, a second reform bill was introduced in the Senate. Despite a call from Senator Specter to delay the bills until the Federal Circuit had a chance to address the Òentire market valueÓ rule and other damages issues in an appeal currently pending before the court, Senator Lehay has been pushing to get the bill out of the committee. Currently, the main point of contention appears to be the damages provision. Late in the month the Senators announced that a proposed compromise may have been reached on language for the damages provisions. They also announced that additional substantive amendments to the bill will be announced in early April. These amendments are expected to address the Òhot issuesÓ of venue, interlocutory appeal of claim construction orders, inequitable conduct, and willful infringement. We will report further on the bill after its provisions solidify.
The Intellectual Property Owners Association (IPO) will be hosting a day and half conference entitled ÒRealities and Myths in Patent Litigation Today: ÔNon-PracticingÕ Patent Owners and Other Issues,Ó on May 28 and 29, at the Grand Hyatt Hotel, in Washington, D.C. Bob Matthews will be speaking at the conference on the issue of injunctive relief for patent infringement in the wake of eBay, addressing in particular the availability of injunctive relief for non-practicing patent owners.
|
Latimer, Mayberry & Matthews IP Law, llp, an ÒAV‰Ó rated law firm, provides legal services to corporations and law firms in the area of U.S. patent and trademark law including: patent litigation consulting services; patent application and prosecution services; investigation, analysis, and opinions of counsel for issues of patent infringement, validity, and enforceability; and patent licensing and portfolio management. Our attorneys have years of dedicated experience in patent litigation and procurement, and have authored numerous articles and publications on the subject, including the eight-volume patent-law treatise Annotated Patent Digest, available on Westlaw. We maintain offices in Blacksburg, VA and Herndon, VA, while assisting clients nationally in matters of federal patent law. For questions regarding our patent litigation consulting services, the content of Patent Happeningsï, or the Annotated Patent Digest, please contact Robert A. Matthews, Jr. (434.525.1141; robert.matthews@latimerIP.com). For further details on the firm, please visit our website at www.latimerIP.com or contact any of the following: Matthew Latimer (703.463.3072), Michele Mayberry (540.953.7075), or Timothy Donaldson (703.463.3073). For questions regarding our trademark practice, please contact Janice Housey (703.463.3074). |
|
This newsletter is for informational purposes only and is a marketing publication of Latimer, Mayberry & Matthews IP Law, llp. It is intended to alert the recipients to developments in the law and does not constitute legal advice or a legal opinion on any specific facts or circumstances. The contents are intended as general information only. This newsletter may be copied by and/or transmitted to others freely by its recipients, but only in its entirety so as to include proper recognition of the authors. The information presented in this newsletter is, to the best of our knowledge, accurate as of publication. However, we take no responsibility for inaccuracies or other errors present in this newsletter. The information in this newsletter does not necessarily reflect the opinions of the firm, its lawyers or its clients. This newsletter may be considered ADVERTISING MATERIAL in some jurisdictions. ÒAV‰Ó peer-reviewed rating given by Martindale-Hubbell. According to Martindale-Hubbell: ÒAn AV rating is a significant accomplishment Ñ a testament to the fact that a lawyer's peers rank him or her at the highest level of professional excellence.Ó ÒMartindale-Hubbell is the facilitator of a peer review rating process. Ratings reflect the confidential opinions of members of the Bar and the Judiciary. Martindale-Hubbell Ratings fall into two categories Ñ legal ability and general ethical standards.Ó ÒCV, BV and AV are registered certification marks of Reed Elsevier Properties Inc., used in accordance with the Martindale-Hubbell certification procedures, standards and policies.Ó |
[1]
See generally, Robert A. Matthews, Jr.,
Annotated Patent Digest ¤ 10:128 The Enactment of ¤ 271(f) [hereinafter APD]. Section 271(f)(1) provides that ÒWhoever
without authority supplies or causes to be supplied in or from the United
States all or a substantial portion of the components of a patented invention,
where such components are uncombined in whole or in part, in such manner as to
actively induce the combination of such components outside of the United States
in a manner that would infringe the patent if such combination occurred within
the United States, shall be liable as an infringer.Ó